Syntara Ltd (ASX: SNT) has secured inclusion in a $3 million government-funded pancreatic cancer trial, marking its fourth externally-funded clinical programme without requiring cash contribution from the company. The Garvan Institute of Medical Research has been awarded the grant under the Medical Research Future Fund (MRFF) to conduct two multicentre studies in advanced pancreatic cancer, one of which will test Syntara’s anti-fibrotic drug amsulostat alongside standard chemotherapy.
Syntara Secures Place in $3 Million Government-Funded Pancreatic Cancer Programme
The Syntara pancreatic cancer trial represents strategic expansion into solid tumours with zero capital outlay from the biotech firm. Under the collaboration, Syntara will supply amsulostat (SNT-5505) plus scientific and clinical expertise, with the $3 million MRFF grant covering all study costs. This capital-efficient approach demonstrates how competitive grant success can advance multiple programmes simultaneously whilst protecting shareholder value.
Recruitment is expected to commence mid-2026 across three leading New South Wales cancer centres: Westmead Hospital, St Vincent’s Hospital Sydney, and Wollongong Hospital. The Phase 1/2 trial will evaluate amsulostat in combination with standard-of-care chemotherapy for advanced pancreatic ductal adenocarcinoma (PDAC), the most common and lethal form of pancreatic cancer.
The programme builds on preclinical research led by the Garvan Institute and published in Nature Cancer (see ASX announcement 29 August 2023). That research demonstrated that targeting tumour fibrosis weakens the dense barrier surrounding pancreatic tumours, enabling chemotherapy drugs to penetrate more effectively and destroy cancer cells whilst reducing invasion and metastasis.
CEO Commentary
“Whilst our focus remains on the treatment of haematological malignancies like MF and MDS, the pre-clinical work conducted by Professor Cox and others regarding chemotherapy resistant tumours is compelling. We are delighted that the MRFF have seen the value of translating this work into the clinic,” said Gary Phillips, Chief Executive Officer of Syntara.
When big ASX news breaks, our subscribers know first
Breaking Down Dense Tumour Barriers: The Science Behind the Trial
Pancreatic ductal adenocarcinoma remains one of the deadliest cancers, with poor long-term survival outcomes driven largely by treatment resistance. A key obstacle is the fibrous “stromal” barrier that forms a fortress around tumours, limiting drug delivery and supporting tumour progression. This dense, scar-like tissue prevents chemotherapy from reaching cancer cells effectively.
Amsulostat targets lysyl oxidase (LOX) enzymes, which are responsible for building and strengthening this protective barrier. LOX enzymes act like molecular “scaffolding builders”, creating the structural framework that hardens tumour tissue. By inhibiting these enzymes, amsulostat aims to weaken the barrier and allow chemotherapy to penetrate more effectively.
How the Combination Therapy Works:
- Dense fibrosis blocks chemotherapy – Scar tissue creates a physical barrier preventing drug penetration
- Amsulostat inhibits LOX enzymes – Blocking the enzymes that build and maintain the protective barrier
- Weakened barrier allows drug delivery – Chemotherapy can reach and destroy cancer cells more effectively
The approach addresses a massive unmet clinical need where standard treatments often fail due to this physical barrier. The scientific rationale has been validated through peer-reviewed publication in Nature Cancer, providing independent confirmation of the mechanism before entering human trials.
Understanding the Tumour Microenvironment
The tumour microenvironment refers to the cellular “neighbourhood” surrounding cancer cells. In pancreatic cancer, this environment becomes dominated by excessive scar tissue (fibrosis), which tumours exploit for protection and growth.
Lysyl oxidase enzymes drive this process by cross-linking collagen fibres, creating rigid structures that shield cancer cells from immune attack and chemotherapy. Amsulostat’s anti-fibrotic action aims to restore a more normal tissue environment where treatments can work as intended.
From Lab Bench to Bedside: Study Design and Precision Medicine Approach
The Phase 1/2 trial will test amsulostat safety, tolerability, and clinical activity when combined with standard chemotherapy regimens for advanced pancreatic cancer. Beyond traditional efficacy measures, the study incorporates a precision medicine strategy through deep molecular and genetic profiling of tumour and blood samples collected before and during treatment.
This biomarker analysis aims to identify which patient subgroups are most likely to benefit from the combination therapy, potentially enabling more targeted treatment strategies in future clinical development. By understanding the genetic and molecular signatures associated with response, researchers can refine patient selection criteria and increase the probability of regulatory approval.
Academic Leadership
“Pancreatic cancer creates a dense, scar-like barrier that diminishes patient response to therapy. Through our long-standing collaboration with Syntara, we’ve identified a promising strategy to target lysyl oxidases, the key enzymes that build and strengthen this scar tissue. The proposed phase I/II trial with amsulostat in combination with chemotherapy represents a critical step in validating and translating our laboratory findings into new treatment options for patients with advanced pancreatic cancer,” said Professor Thomas Cox, Laboratory Head at the Garvan Institute and Conjoint Professor at St Vincent’s Clinical School, UNSW Sydney.
Three Primary Study Objectives:
- Safety and tolerability assessment of amsulostat combined with chemotherapy
- Clinical activity signals indicating tumour response or disease stabilisation
- Biomarker and patient subgroup identification to guide future targeted therapy development
Beyond Pancreatic Cancer: Broader Solid Tumour Potential
The anti-fibrotic approach may have applications across multiple solid cancers characterised by dense stromal barriers that impede treatment delivery. Certain breast, liver, and lung cancers exhibit similar fibrotic characteristics that contribute to chemotherapy resistance. This positions amsulostat as a potential platform technology rather than a single-indication asset.
The broader applicability is supported by peer-reviewed publications from academic collaborators using amsulostat in preclinical models of various fibrotic cancers. Whilst Syntara’s primary focus remains blood cancers, the solid tumour opportunity represents strategic optionality funded entirely through external grants rather than shareholder capital.
Building a Grant-Funded Pipeline: Syntara’s Non-Dilutive Capital Strategy
The Syntara pancreatic cancer trial marks the fourth clinical programme funded through competitive grant processes, with total non-dilutive capital now exceeding $10 million. This capital-efficient model enables simultaneous advancement of multiple programmes across diverse indications without shareholder dilution, a critical advantage for clinical-stage biotechnology companies where cash preservation determines survival.
Competitive grant success reflects external validation of scientific quality by independent peer review panels and government funding bodies. The MRFF specifically supports translational research with strong preclinical foundations and clear pathways to patient benefit, indicating confidence in both the scientific rationale and execution capability.
| Study Programme | Indication | Funding Source | Expected Data Readout | Significance |
|---|---|---|---|---|
| SNT-4728 | iRBD (Parkinson’s sleep disorder) | Parkinson’s UK grant | Q2 2026 | Topline results |
| Amsulostat | Myelodysplastic syndrome (2 studies) | External grants | H2 2026 | Blood cancer data |
| SNT-9465/SNT-6302 | Skin scarring (2 studies) | External collaboration funding | H2 2026 | Topical applications |
| Amsulostat | Pancreatic cancer | $3M MRFF government grant | Recruitment mid-2026 | Solid tumour expansion |
The 2026 clinical calendar positions Syntara for multiple value-inflection points across a diversified portfolio spanning blood cancers, neurology, dermatology, and oncology. Each catalyst event carries potential to validate platform technologies and expand addressable markets.
The next major ASX story will hit our subscribers first
What This Means for SNT Investors
Syntara’s primary strategic focus remains haematological malignancies, specifically myelofibrosis (MF) and myelodysplastic syndrome (MDS), where the company has established clinical programmes and regulatory pathways. The pancreatic cancer trial represents strategic optionality rather than core focus redirection, providing exposure to high-value solid tumour markets without diverting capital from priority programmes.
The zero-cash-requirement structure exemplifies capital discipline, allowing the company to explore adjacent opportunities whilst preserving runway for lead indications. With five clinical readouts expected throughout 2026, investors face a data-rich period that could validate both the LOX inhibition platform and precision medicine approach across multiple disease areas.
Three Key Investor Takeaways:
- Zero cash outlay expands pipeline into pancreatic cancer markets without diluting existing shareholders or diverting resources from blood cancer programmes
- Five clinical readouts expected in 2026 across blood cancers (MDS), neurology (iRBD), dermatology (scarring), and oncology (pancreatic cancer), providing multiple value catalysts
- Over $10 million in competitive grant funding validates scientific approach and demonstrates management’s ability to leverage external capital for pipeline advancement
The $3 million MRFF award specifically validates the translational potential of Garvan Institute’s preclinical work and positions amsulostat for clinical proof-of-concept in a notoriously difficult-to-treat cancer. Success in identifying responsive patient subgroups through biomarker analysis could accelerate development timelines and increase commercial probability across the broader anti-fibrotic platform.
Want More Biotech Breakthroughs Like This?
Syntara’s grant-funded expansion into pancreatic cancer demonstrates the strategic value of monitoring clinical-stage biotechs before major catalysts emerge. The company faces five potential value-inflection points throughout 2026 across blood cancers, neurology, and oncology—each carrying the potential to validate platform technologies and redefine market positioning.
Join 20,000+ investors receiving FREE breaking news and comprehensive analysis on ASX Biotech and Healthcare stocks through StockWire X Big News Blasts. These email alerts deliver sector-specific developments with the context needed to assess commercial significance before market-wide recognition occurs. Click the “Free Alerts” button in the menu above to receive time-sensitive updates on companies advancing through clinical milestones, regulatory decisions, and partnership announcements that drive valuation changes in the non-resource sectors.